Skip Navigation

Japanese Journal of Clinical Oncology 2004 34(6):312-315; doi:10.1093/jjco/hyh049
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Niibe, Y.
Right arrow Articles by Tanaka, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niibe, Y.
Right arrow Articles by Tanaka, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Foundation for Promotion of Cancer Research

Hyperfractionated Radiation Therapy for Oropharyngeal Carcinoma in a Japanese Population

Yuzuru Niibe1,3, Katsuyuki Karasawa1, Toshio Mitsuhashi2, Hisao Miyashita2 and Yoshiaki Tanaka4,+

1 Department of Radiology and Radiation Oncology and 2 Department of Otolaryngology, Tokyo Metropolitan Komagome Hospital, Tokyo, 3 Deparment of Radiology, Kitasato University School of Medicine, Sagamihara, Kanagawa and 4 Department of Radiology, Nihon University Medical School, Tokyo, Japan

Background: Hyperfractionated radiation therapy is recognized to be a better treatment method, especially regarding local control, than conventional radiation therapy for oropharyngeal carcinoma. However, the survival benefit of hyperfractionated radiation therapy for oropharyngeal carcinoma has not been reported so far. Moreover, patient populations of previous studies were mostly white or African-American, and rarely included Orientals. Thus, the current study is designed to evaluate not only local control but the survival benefit of hyperfractionated radiation therapy for oropharyngeal carcinoma in a Japanese population.

Methods: The eligibility criteria were as follows. The patients were 20 years or older. Performance status ranged from 0 to 2. No patient with double carcinoma was included except those with superficial esophageal carcinoma or advanced carcinoma controlled for at least 2 years after treatment. In our radiation protocol, hyperfractionated radiation therapy was adopted using 1.2 Gy per fraction, two fractions per day (6 h apart), 5 days a week, for a total dose of 66 Gy or more.

Results: Complete response was achieved in all 14 patients with oropharyngeal lesions. In five patients with lymph node metastasis, complete response was achieved in four patients and partial response was achieved in the remaining one. The 3-year loco-regional control rate was 77% and the 3-year overall survival rate was 69%.

Conclusions: Treatment with hyperfractionated radiation therapy is considered superior to conventional radiation therapy with acceptable toxicity for Japanese patients with oropharyngeal carcinoma in terms of loco-regional control rate and overall survival rate.

+ For reprints and all correspondence: Yuzuru Niibe, Department of Radiology, Kitasato University School of Medicine, 1-15-1, Kitasato, Sagamihara-shi, Kanagawa 228-8555, Japan. E-mail: joe-n{at}hkg.odn.ne.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.